Biotech leader Biocon announced Monday that it has launched capsules of Tacrolimus, an immunosuppressant, in the US market.
Tacrolimus is used in the treatment of organ transplant patients. The drug reduces the body’s ability to reject a transplanted organ.
It has been particularly effective in the treatment of kidney transplant patients for more than two decades.
The launch of Tacrolimus capsules, following U.S. Food and Drug Administration (USFDA) approval in November 2020, underscores the company’s relentless pursuit of its mission to make affordable healthcare accessible, Biocon said in a statement.
“The launch of Tacrolimus capsules in the United States is another important milestone for Biocon that reflects our commitment to continually evaluate and expand our portfolio of complex products to serve patients,” said Siddharth Mittal, CEO and Managing Director of Biocon Ltd.
